Based on sequences for hundreds of E. coli ST131 lineage isolates, researchers propose a model that involves negative frequency-dependent selection on accessory parts of the genome.
Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.
The company posted revenues of $513.9 million for the quarter compared to $530.7 million in Q1 2018, below the average Wall Street estimate of $545.3 million.
With the approval of its ThyraMIR diagnostic assay, the firm said that physicians will have access to its thyroid product suite across several specimen types.
LabCorp will further invest in OmniSeq as part of the deal, which covers distribution of the latter's immune profiling and pan-cancer next-generation sequencing tests.
Investigators identified a set of inflammatory proteins that appears to coincide with current and future risk of end-stage renal disease in individuals with diabetes.
The company launched last month with initial financing of $35 million and licenses to CRISPR and synthetic biology technology from the Broad and Harvard.
The test is based on RNA sequencing and is used to differentiate between idiopathic pulmonary fibrosis and other lung diseases in order to avoid surgery.
The study researchers further reported that high matching scores predicted both better progression-free and overall survival.
Concordance numbers and early evidence of clinical impact from a 100-patient first phase were sufficient to expand to another 450 individuals.
Under the terms of the settlement, Enzo Life Sciences will receive $14 million in exchange for granting global licenses to Hologic and Grifols.
Starting with a head and neck cancer patient who showed an impressive response to pembrolizumab, researchers profiled gene fusion neoantigens in several tumor types.
A team compared expression in duodenum samples from active celiac cases, cases in remission, and unaffected controls, identifying active disease-related expression shifts.
BrightEdge was founded by the American Cancer Society to invest in for-profit companies developing novel cancer therapeutics and diagnostics.
With NetApp certification, sequence file compression software vendor PetaGene can improve the speed and scalability of genomic data processing for its customers.
In a study of more than 300,000 participants, middle-aged individuals with a high polygenic score weighed nearly 30 pounds more on average than those with lower scores.
By sequencing several individuals with unexplained pancreas and brain development problems, investigators identified a recurrent missense mutation in the CNOT1 gene.
Sequence data for nine Crusaders buried in Lebanon identified individuals with European, Near Eastern, or mixed ancestry, but no lasting genetic effect on the wider population.
The Life Sciences business grew 10 percent year over year, while the Diagnostics business inched up 1 percent.
The firm is selling more than 5.2 million shares at an offering price of $19 per share.
At Bio-IT World, Sage Bionetworks' John Wilbanks called on the research community to adopt the OMOP and FHIR standards so data becomes more useful to other scientists.
Researchers found that both CBEs and ABEs can cause transcriptome-wide RNA edits, which has implications for the research and therapeutic uses of base editors.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
The New York Times Magazine examines gender discrimination at the Salk Institute.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.